Search

Displaying results 2661 - 2670 of 6076 in total
  1. Drug

    Metenkefalin

    go.drugbank.com/drugs/DB12668
    Investigational

    [A203210] Metenkefalin, along with [tridecactide], are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.[L13874,L13877]

    Categories: Experimental Unapproved Treatments for COVID-19
  2. Drug

    Sotalol

    go.drugbank.com/drugs/DB00489
    ApprovedInvestigational

    [L6334] A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm

  3. Drug

    Tapentadol

    go.drugbank.com/drugs/DB06204
    ApprovedInvestigational

    [L47291] Used in the management of pain, tapentadol is typically reserved for patients who have limited alternative treatment options.

  4. Drug

    Typhoid Vaccine Live

    go.drugbank.com/drugs/DB11050
    ApprovedInvestigational

    Salmonella typhi Ty21a live antigen is a live attenuated vaccine for oral administration only. It contains the attenuated strain *Salmonella typhi* Ty21a.

  5. Drug

    Microcrystalline cellulose

    go.drugbank.com/drugs/DB14158
    ApprovedInvestigational

    As a raw material, it forms the basis for many derivatives used in chromatography, ion exchange materials, explosives manufacturing, and pharmaceutical preparations.

  6. Drug

    Salicylamide

    go.drugbank.com/drugs/DB08797
    Approved

    Salicylamide is the common name for the substance o-hydroxybenzamide, or amide of salicyl. Salicylamide is a non-prescription drug with analgesic and antipyretic properties.

  7. Drug

    Attapulgite

    go.drugbank.com/drugs/DB01574
    ApprovedVet approvedWithdrawn

    For that reason, it has often been used in antidiarrheal medications. Until 2003, it was the active ingredient used in Kaopectate, before that product was reformulated with bismuth subsalicylate.

  8. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. … [L3344] On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic

  9. Drug

    ING-1

    go.drugbank.com/drugs/DB05831
    Investigational

    It is an attractive target for immunotherapy.

  10. Drug

    Mecasermin rinfabate

    go.drugbank.com/drugs/DB14751
    ApprovedInvestigational

    In 2007 Insmed withdrew their application for a marketing authorization with The European Medicines Agency[F4075]. … Mecasermin rinfabate is approved for severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH)[A176020].